EP1406631A4 - Dopamine receptor ligands and therapeutic methods based thereon - Google Patents

Dopamine receptor ligands and therapeutic methods based thereon

Info

Publication number
EP1406631A4
EP1406631A4 EP02744349A EP02744349A EP1406631A4 EP 1406631 A4 EP1406631 A4 EP 1406631A4 EP 02744349 A EP02744349 A EP 02744349A EP 02744349 A EP02744349 A EP 02744349A EP 1406631 A4 EP1406631 A4 EP 1406631A4
Authority
EP
European Patent Office
Prior art keywords
methods based
therapeutic methods
receptor ligands
dopamine receptor
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02744349A
Other languages
German (de)
French (fr)
Other versions
EP1406631A2 (en
Inventor
Shaomeng Wang
Judith Varady
Xihan Wu
Ji Min
Ke Ding
Beth Levant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of EP1406631A2 publication Critical patent/EP1406631A2/en
Publication of EP1406631A4 publication Critical patent/EP1406631A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP02744349A 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon Withdrawn EP1406631A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29744501P 2001-06-13 2001-06-13
US297445P 2001-06-13
PCT/US2002/018914 WO2002100350A2 (en) 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon

Publications (2)

Publication Number Publication Date
EP1406631A2 EP1406631A2 (en) 2004-04-14
EP1406631A4 true EP1406631A4 (en) 2005-03-23

Family

ID=23146337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02744349A Withdrawn EP1406631A4 (en) 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon

Country Status (3)

Country Link
EP (1) EP1406631A4 (en)
CA (1) CA2450315A1 (en)
WO (1) WO2002100350A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10226459A1 (en) * 2002-06-13 2004-01-08 Neurobiotec Gmbh Use of dopamine partial agonists to treat restless legs syndrome
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ES2529038T3 (en) 2004-05-07 2015-02-16 Merck Sharp & Dohme Corp. HIV integrase inhibitors
DK2317852T3 (en) * 2008-07-16 2015-03-23 Richter Gedeon Nyrt PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
CA2761961C (en) 2009-05-22 2017-10-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
EP2571353B1 (en) 2010-05-21 2017-08-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
HUE059372T2 (en) 2015-06-17 2022-11-28 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
EP3313407B1 (en) * 2015-08-19 2023-07-19 East Carolina University Treatment and management of augmentation in restless legs syndrome
CN105418605B (en) * 2015-11-23 2017-12-22 东南大学 A kind of preparation method of improved nitrogenous tricyclic antidepressants dopamine D 3 receptor part
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
WO1994020497A1 (en) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives
WO1996004250A1 (en) * 1994-08-05 1996-02-15 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997040015A1 (en) * 1996-04-23 1997-10-30 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor subtype specific ligands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498849A (en) * 1966-10-05 1970-11-15 Ciba Geigy Pyrazino 1 2-a quinolines having adrenolytic sedative and antihyperten - sive activity
AU4547796A (en) * 1995-02-03 1996-08-21 Sankyo Company Limited Hexahydropyrazinoquinoline derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
WO1994020497A1 (en) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives
WO1996004250A1 (en) * 1994-08-05 1996-02-15 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997040015A1 (en) * 1996-04-23 1997-10-30 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor subtype specific ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G.B. SINGH ET AL.: "antihypertensive and cns depressant properties of 3-(gamma-p-fluorobenzoylpropyl)2,3,4,4a,5,6-hexahydro-1(h)-pyrazino(1,2-a)quinoline hydrochloride", EXPERIENTIA., vol. 29, no. 12, 15 December 1973 (1973-12-15), CHBIRKHAUSER VERLAG. BASEL., pages 1529 - 30, XP002292999 *
G.B. SINGH ET AL.: "pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a5,6,hexahydro-1h-pyrazino(1,2-a)quinoline hydrochloride", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., vol. 28, no. 9, 1978, DEEDITIO CANTOR. AULENDORF., pages 1641 - 4, XP002293000 *
I. BOYFIELD ET AL.: "n-(substituted-phenyl)piperazines:", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 11, 1996, GB, pages 1227 - 32, XP004134859 *
V.ARUNA RAO: "agents acting on the central nervous system. XIII:", JOURNAL OF MEDICINAL CHEMISTRY., vol. 13, no. 3, 1970, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 516 - 22, XP002292998 *

Also Published As

Publication number Publication date
CA2450315A1 (en) 2002-12-19
WO2002100350A3 (en) 2003-05-22
EP1406631A2 (en) 2004-04-14
WO2002100350A2 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
HK1205748A1 (en) Therapeutic epitopes and uses thereof
IL158808A0 (en) 5-ht receptor ligands and uses thereof
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
GB0111872D0 (en) Therapeutic agents and methods
HK1127544A1 (en) Repositioning apparatus and garment
GB0118383D0 (en) Therapeutic methods
EP1406631A4 (en) Dopamine receptor ligands and therapeutic methods based thereon
HK1089446A1 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
GB0219660D0 (en) Therapeutic use
EP1407771A4 (en) Sophoridine and use thereof as an analgesic
AU2002345707A1 (en) Dopamine receptor ligands and therapeutic methods based thereon
EP1569928A4 (en) Therapeutic compounds and methods
AU2003231937A8 (en) Therapeutic methods
GB0128122D0 (en) Therapeutic use
GB0123991D0 (en) New therapeutic use
GB0106434D0 (en) Novel estrogwen receptor ligands and methods II
GB0211205D0 (en) Receptor and ligand
GB0214588D0 (en) Therapeutic device
SI1648899T1 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
GB0211204D0 (en) Receptor and its ligand
GB0216754D0 (en) Therapeutic methods and means
GB0209039D0 (en) Therapeutic methods and means
GB0100163D0 (en) Novel estrogen receptor ligands and methods
GB0128089D0 (en) Therapeutic use
GB0128090D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 471/04 B

Ipc: 7C 07D 241/02 B

Ipc: 7C 07D 241/36 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61K 31/50 B

Ipc: 7A 61K 31/495 A

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEVANT, BETH

Inventor name: DING, KE

Inventor name: MIN, JI

Inventor name: WU, XIHAN

Inventor name: VARADY, JUDITH

Inventor name: WANG, SHAOMENG

A4 Supplementary search report drawn up and despatched

Effective date: 20050208

17Q First examination report despatched

Effective date: 20071017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080228